Nachrichten zur BioArctic AB Aktie

Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024

Stockholm, Sweden, April 24, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…

BioArctic and Eisai sign research evaluation agreement regarding BAN2802

Stockholm, Sweden, April 20, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai…

Notice of Annual General Meeting in BioArctic AB (publ)

The board of directors of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held…

AAX Biotechs Technology to be Utilized in BioArctic’s Research Project

Biotech company AAX Biotech, specializing in innovative technologies for improving antibody-based medicines, is excited to announce that BioArctic AB, a…

The Nomination Committees proposal for the election of Board members and Chairperson of the Board in BioArctic AB

Stockholm April 16, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic…

BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm

Stockholm, Sweden, April 10, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) commitment to its Sustainable Innovation approach –…

Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed

Stockholm, Sweden, April 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has…

Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons

Stockholm, Sweden March 22, 2024 – BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Oral…

Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease

Stockholm, Sweden, March 19, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctics founder, Professor Lars…

BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press conference

Stockholm, Sweden, March 7, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published a presentation including…

Number of shares and votes in BioArctic AB (publ) as of February 29, 2024

Stockholm, February 29, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during February issued…

Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

Stockholm, February 29, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company and its partner…

BioArctics CEO Gunilla Osswald Winner of The Arthur D. Little Nordic Life Science Award

Stockholm, Sweden, February 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today proudly announced that CEO, Gunilla Osswald,…

Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023

Stockholm, Sweden, February 6, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report…

Invitation to presentation of BioArctic’s fourth quarter report for October - December 2023 on February 14 at 9.30 a.m. CET

Stockholm, Sweden, February 5, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s fourth quarter report for…

The European Medicines Agency’s Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab

Stockholm, Sweden, January 11, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Scientific…

Number of shares and votes in BioArctic AB (publ) as of December 29, 2023

Stockholm, December 29, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during December issued…

LEQEMBI® to be launched in Japan for Alzheimer’s disease on December 20

Stockholm, Sweden, December 13, 2023 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that LEQEMBI (lecanemab)…

Lecanemab winner in two categories at The Scrip Awards 2023

Stockholm, November 20, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded…

Interim Report for the period July – September 2023

LEQEMBI launched in the US Events during the third quarter 2023 · In July, the FDA approved LEQEMBI® for the…

Update relating to LEQEMBI® from Eisai’s investor presentation of their quarterly report published today

Stockholm, Sweden, November 7, 2023 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today held a presentation on…

LEQEMBI® Q3 2023 sales published – 0.4 billion yen recorded in the period

Stockholm, Sweden, November 7, 2023 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report…

Invitation to presentation of BioArctic’s third quarter report for July - September 2023 on November 8 at 9.30 a.m. CET

Stockholm, Sweden, November 1, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s third quarter report for…

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD

Stockholm, October 25, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data on the…

Lecanemab named one of the worlds best inventions in 2023 by TIME

Stockholm, October 24, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai are proud to announce today…

BioArctic presents Nomination Committee

Stockholm, Sweden, October 20, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on June 1, 2023,…

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD

Stockholm, October 16, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data from the…

Number of shares and votes in BioArctic AB (publ) as of September 29, 2023

Stockholm, September 29, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during September issued…

Eisai’s regulatory progress brings cash flow for BioArctic

Yesterday, the Japanese pharmaceutical giant Eisai announced that Leqembi has been approved in Japan. The intravenous infusion treatment has been…

“LEQEMBI[®] Intravenous Infusion” approved for the treatment of Alzheimer’s disease in Japan

Stockholm, September 25, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that “LEQEMBI[®] Intravenous Infusion”…

Interim Report for the period April – June 2023

LEQEMBI® approved in the US – the worlds first fully approved disease-modifying treatment for Alzheimers disease   Events during the second quarter…

Number of shares and votes in BioArctic AB (publ) as of May 31, 2023

Stockholm, May 31, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during May issued…

BioStock Life Science Spring Summit with BioArctic

Do not miss BioArctics presentation at the BioStock Life Science Spring Summit, today May 31 at 12.30. The event starts at…

BioArctic: Marketing Authorization Application For Lecanemab Submitted In Great Britain

WESTON (dpa-AFX) - BioArctic ABs partner Eisai said that they have submitted a Marketing Authorisation Application for lecanemab, an investigational…

Correction of press release: BioArctic repurchases employee stock options from CEO

In the press release the company published at 18.00 CET on May 16, there was an incorrect value of the…

BioArctic repurchases employee stock options from CEO

Stockholm, May 16, 2023 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) today announced that the companys Board of Directors…

Notice of Annual General Maating in BioArctic AB (publ)

The Board of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday,…

Number of shares and votes in BioArctic AB (publ) as of February 28, 2023

Stockholm, February 28, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during February issued…

BioArctic hires Anders Martin-Löf as new CFO

STOCKHOLM, Feb. 28, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the company has recruited…

BioArctic hires Anders Martin-Löf as new CFO

Stockholm, February 28, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has recruited Anders…

BioArctic: Lecanemab receives priority review status in Japan

STOCKHOLM, Jan. 30, 2023 /PRNewswire/ -- BioArctic ABs (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the application…

BioArctic moves to Nasdaq Stockholm Large Cap

STOCKHOLM, Jan. 2, 2023 /PRNewswire/ -- As of today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will move to the…

BioArctic moves to Nasdaq Stockholm Large Cap

Stockholm, January 2, 2023 – As of today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will move to the Large…

Number of shares and votes in BioArctic AB (publ) as of November 30, 2022

Stockholm, November 30, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during November issued…

BioArctic expands portfolio with alpha-synuclein Brain Transporter project

STOCKHOLM, Nov. 17, 2022 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company is expanding…

BioArctic expands portfolio with alpha-synuclein Brain Transporter project

Stockholm, November 17, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company is expanding its…

BioArctic receives new patent in the US for blood-brain barrier transport technology

STOCKHOLM, Nov. 14, 2022 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and…

BioArctic receives new patent in the US for blood-brain barrier transport technology

Stockholm, November 14, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark…

Lars Lannfelt and Pär Gellerfors divest shares in BioArctic

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,…

BioArctic presents Nomination Committee

Stockholm, Sweden, October 18, 2022 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 5, 2022,…